OraSure Technologies, Inc.

386 articles with OraSure Technologies, Inc.

• nRichDX and OraSure Advance Commercial Collaboration to Create Preanalytical Solutions for the Urine-based MDx Market

  3/27/2023

  nRichDX and OraSure Technologies, Inc., have advanced a commercial collaboration to validate and co-promote their products for researchers developing liquid biopsy applications using first-void urine samples.

• OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability

  2/14/2023

  OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three months ended December 31, 2022.

• 2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET

  2/7/2023

  OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023.

• OraSure Technologies Continues its Dedication to Ending the HIV Epidemic

  12/1/2022

  OraSure Technologies, Inc., a global leader in the fight against HIV, will ring the closing bell for the Nasdaq Stock Market this afternoon in honor of World AIDS Day.

• OraSure Technologies to Present at Stephens Annual Investment Conference

  11/14/2022

  OraSure Technologies, Inc. announced that Ken McGrath, Chief Financial Officer, will participate in a fireside chat at the Stephens Annual Investment Conference on November 17, 2022 at 9:00 am ET.

• OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year

  11/8/2022

  OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three months ended September 30, 2022.

• OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)

  11/3/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Company received U.S. FDA clearance for its ORAcollect®•Dx saliva collection device for OTC (i.e. direct-to-consumer) use.

• 2022 Third Quarter Earnings Conference Call Tuesday, November 8, 2022, 5:00 p.m. ET

  11/1/2022

  OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2022 third quarter financial results and certain business developments for 5:00 pm ET on Tuesday, November 8, 2022.

• OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

  9/20/2022

  OraSure Technologies, Inc. announced that the Company has been selected to provide its OraQuick® In-Home HIV tests in support of the Centers for Disease Control and Preventions “Together Take Me Home,” HIV self-test program.

• OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year

  8/9/2022

  OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three months ended June 30, 2022.

• OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET

  8/2/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 second quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Tuesday, August 9, 2022.

• OraSure’s Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack

  7/28/2022

  OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced its ongoing commitment to fight the hepatitis C epidemic.

• OraSure Technologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 08, 2022

  6/8/2022

  OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced that on June 4, 2022, OraSure’s Board of Directors granted Carrie Eglinton Manner, the Company’s newly appointed President and Chief Executive Officer, an inducement award.

• InteliSwab® COVID-19 Rapid Test Selected by Federal Government for Nationwide School TestingThe rapid at-home COVID-19 test is authorized for ages 2 and up

  5/25/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab® COVID-19 Rapid Test has been selected by the U.S. Department of Health and Human Services (HHS) to be distributed to schools nationwide.

• InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants

  5/17/2022

  OraSure Technologies, Inc. announced that its InteliSwab® COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants with similar levels of detection to the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta, Gamma and Omicron BA.1.

• OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue

  5/10/2022

  OraSure Technologies, Inc. announced its financial results for the three months ended March 31, 2022.

• OraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ET

  5/3/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 first quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, May 10, 2022.

• OraSure Technologies’ Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome Samples

  4/7/2022

  OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today its OMNIgene®·GUT Dx (OMD-200) microbiome collection device, has been granted de novo authorization from the U.S. Food and Drug Administration (FDA) and the Company is commercially launching the device.

• OraSure Technologies’ Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples

  3/31/2022

  OraSure Technologies, Inc. announced that its’ Diversigen subsidiary has launched a new service to provide metatranscriptomic sequencing and analysis of gut microbiome samples.

• OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role

  3/22/2022

  OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its Board of Directors has appointed Nancy Gagliano, MD to serve as interim Chief Executive Officer, effective April 1, 2022.